Biodesix Inc (BDSX)

May 02, 2025

Biodesix, Inc. (NASDAQ:BDSX) Receives $2.95 Average Target Price from Analysts - Defense World

May 02, 2025

May 01, 2025

Biodesix, Inc. (NASDAQ:BDSX) Receives $2.95 Average Price Target from Brokerages - MarketBeat

May 01, 2025

May 01, 2025

Canaccord Genuity Group Lowers Biodesix (NASDAQ:BDSX) Price Target to $2.50 - MarketBeat

May 01, 2025

May 01, 2025

Geode Capital Management LLC Increases Position in Biodesix, Inc. (NASDAQ:BDSX) - Defense World

May 01, 2025

Apr 29, 2025

Biodesix (BDSX) Target Price Reduced by Canaccord Amid Market Ch - GuruFocus

Apr 29, 2025

Apr 29, 2025

Wells Fargo & Company MN Has $1.28 Million Holdings in Biodesix, Inc. (NASDAQ:BDSX) - Defense World

Apr 29, 2025

Apr 29, 2025

Biodesix to Report First Quarter 2025 Financial Results on May 1 - GuruFocus

Apr 29, 2025

Apr 29, 2025

Biodesix, Inc. to Release First Quarter 2025 Financial Results on May 13 - Nasdaq

Apr 29, 2025

Apr 29, 2025

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - Bluefield Daily Telegraph

Apr 29, 2025

Apr 29, 2025

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewswire Inc.

Apr 29, 2025

Apr 29, 2025

Biodesix and Bio-Rad Drive Advances in ctDNA-Based Cancer Therapies - Technology Networks

Apr 29, 2025

Apr 28, 2025

Ratios Uncovered: Breaking Down Biodesix Inc (BDSX)’s Trailing Twelve Months Metrics - DWinneX

Apr 28, 2025

Apr 27, 2025

Silverarc Capital Management LLC Acquires 771,187 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat

Apr 27, 2025

Apr 25, 2025

Biodesix Inc (BDSX) Stock: From Low to High in 52 Weeks - investchronicle.com

Apr 25, 2025

Apr 24, 2025

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types - MSN

Apr 24, 2025

Apr 24, 2025

Biodesix Inc [BDSX] Chief Accounting Officer makes an insider purchase of 3,630 shares worth 3355.0. - knoxdaily.com

Apr 24, 2025

Apr 24, 2025

Biodesix and Bio-Rad publish data linking ctDNA changes to treatment outcomes in solid tumors - Select Science

Apr 24, 2025

Apr 24, 2025

Is Biodesix Inc (BDSX) worth investing in despite its overvalued state? - uspostnews.com

Apr 24, 2025

Apr 23, 2025

Market Resilience: Biodesix Inc (BDSX) Finishes Weak at 0.49, Down -2.00 - DWinneX

Apr 23, 2025

Apr 23, 2025

Biodesix partner, Friends of Cancer Research, publishes data in - GuruFocus

Apr 23, 2025

Apr 23, 2025

Biodesix and Bio-Rad Laboratories Collaborate on Research Revealing ctDNA's Role in Cancer Treatment Outcomes - Nasdaq

Apr 23, 2025

Apr 23, 2025

Biodesix partner, Friends of Cancer Research, publishes - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

Major Clinical Trial Proves ctDNA Testing Accurately Predicts Cancer Treatment Outcomes in Breakthrough Study - Stock Titan

Apr 23, 2025

Apr 19, 2025

Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding - simplywall.st

Apr 19, 2025

Apr 17, 2025

Biodesix Announces Board Member Resignations - TipRanks

Apr 17, 2025

Apr 17, 2025

Biodesix, Inc. Announces Director and Committee Resignations - marketscreener.com

Apr 17, 2025

Apr 10, 2025

Samjo Management LLC Makes New Investment in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat

Apr 10, 2025

Apr 07, 2025

Biodesix Inc [BDSX] stock was sold by Vazquez Chris at the price of US$3355.0 - knoxdaily.com

Apr 07, 2025

Apr 04, 2025

Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.5% in March - MarketBeat

Apr 04, 2025

Apr 03, 2025

HighTower Advisors LLC Acquires 22,500 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World

Apr 03, 2025

Apr 03, 2025

AIGH Capital Management LLC Buys 500,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat

Apr 03, 2025

Apr 02, 2025

Closing Figures Unveiled: Biodesix Inc (BDSX) Drop -3.06, Closes at 0.61 - DWinneX

Apr 02, 2025

Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 01, 2025

Mar 31, 2025

BDSX stock touches 52-week low at $0.63 amid market challenges - Investing.com

Mar 31, 2025

Mar 28, 2025

Perkins Capital Management Inc. Purchases 335,429 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat

Mar 28, 2025

Mar 28, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 28, 2025

Mar 20, 2025

Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update - MarketBeat

Mar 20, 2025

Mar 17, 2025

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier - Business Wire

Mar 17, 2025

Mar 17, 2025

Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 24.6% in February - Defense World

Mar 17, 2025

Mar 17, 2025

Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference - Business Wire

Mar 17, 2025

Mar 16, 2025

Biodesix chief commercial officer sells shares worth $16,198 - MSN

Mar 16, 2025

Mar 11, 2025

Q1 Earnings Estimate for Biodesix Issued By William Blair - MarketBeat

Mar 11, 2025

Mar 08, 2025

Biodesix's (BDSX) "Outperform" Rating Reaffirmed at William Blair - MarketBeat

Mar 08, 2025